User menu

Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis

Bibliographic reference Gibson, C. Michael ; Pride, Yuri B. ; Aylward, Philip E. ; Col, Jacques ; Goodman, Shaun G. ; et. al. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. In: Journal of Thrombosis and Thrombolysis : an international journal for clinicians and scientists, Vol. 27, no. 1, p. 11-17 (2009)
Permanent URL
  1. Antman EM, DeMets D, Loscalzo J (2005) Cyclooxygenase inhibition and cardiovascular risk. Circulation 112(5):759–770. doi: 10.1161/CIRCULATIONAHA.105.568451
  2. Gaziano JM, Gibson CM (2006) Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. Am J Cardiol 97(9A):23–29. doi: 10.1016/j.amjcard.2006.02.020
  3. Cronberg S., Wallmark E., Söderberg I., Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans, 10.1111/j.1600-0609.1984.tb02390.x
  4. Bjorkman DJ (1998) The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 105(1B):8S–12S. doi: 10.1016/S0002-9343(98)00069-2
  5. Patrono C, Coller B, Dalen JE et al (2001) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119(1)(Suppl):39S–63S. doi: 10.1378/chest.119.1_suppl.39S
  6. Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321(3):129–135
  7. Weisman SM, Graham DY (2002) Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 162(19):2197–2202. doi: 10.1001/archinte.162.19.2197
  8. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86
  9. Hayden Michael, Pignone Michael, Phillips Christopher, Mulrow Cynthia, Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force, 10.7326/0003-4819-136-2-200201150-00016
  10. Hebert PR, Hennekens CH (2000) An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med 160(20):3123–3127. doi: 10.1001/archinte.160.20.3123
  11. Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311(19):1206–1211
  12. Kurth T, Glynn RJ, Walker AM et al (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108(10):1191–1195. doi: 10.1161/01.CIR.0000087593.07533.9B
  13. MacDonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361(9357):573–574. doi: 10.1016/S0140-6736(03)12509-3
  14. Kimmel SE, Berlin JA, Reilly M et al (2004) The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 43(6):985–990. doi: 10.1016/j.jacc.2003.08.064
  15. Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809–1817. doi: 10.1056/NEJMoa003199
  16. Gislason GH, Jacobsen S, Rasmussen JN et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113(25):2906–2913
  17. Antman EM, Morrow DA, McCabe CH et al (2005) Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial infarction study 25 (ExTRACT-TIMI 25). Am Heart J 149(2):217–226. doi: 10.1016/j.ahj.2004.08.038
  18. Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354(14):1477–1488
  19. Hensrud DD, Engle DD, Scheitel SM (1999) Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 74(5):443–447
  20. Eliason BC, Myszkowski J, Marbella A, Rasmann DN (1996) Use of dietary supplements by patients in a family practice clinic. J Am Board Fam Pract 9(4):249–253
  21. Ray WA, Stein CM, Byrd V et al (2001) Educational program for physicians to reduce use of non-steroidal anti-inflammatory drugs among community-dwelling elderly persons: a randomized controlled trial. Med Care 39(5):425–435. doi: 10.1097/00005650-200105000-00003
  22. Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26(Suppl 56):18–24
  23. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287(3):337–344. doi: 10.1001/jama.287.3.337
  24. Rao G. H., Johnson G. G., Reddy K. R., White J. G., Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin, 10.1161/01.atv.3.4.383
  25. Van Hecken A, Schwartz JI, Depre M et al (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40(10):1109–1120
  26. Whelton A (2006) Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease. Am J Cardiol 97(9A):3–9. doi: 10.1016/j.amjcard.2006.02.017
  27. Whelton Andrew, Hamilton Cindy W., Nonsteroidal Anti-Inflammatory Drugs: Effects on Kidney Function, 10.1002/j.1552-4604.1991.tb03743.x
  28. Whelton A (2001) Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 110(Suppl 3A):33S–42S. doi: 10.1016/S0002-9343(00)00699-9
  29. Brater DC (1999) Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 107(6A):65S–70S. doi: 10.1016/S0002-9343(99)00369-1 discussion S–1S
  30. Banerjee S, Compton AP, Hooker RS et al (2008) Cardiovascular outcomes in male veterans with rheumatoid arthritis. Am J Cardiol 101(8):1201–1205. doi: 10.1016/j.amjcard.2007.11.076
  31. Dhawan SS, Quyyumi AA (2008) Rheumatoid arthritis and cardiovascular disease. Curr Atheroscler Rep 10(2):128–133. doi: 10.1007/s11883-008-0019-x
  32. Choi HK, Curhan G (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116(8):894–900. doi: 10.1161/CIRCULATIONAHA.107.703389
  33. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH (2008) Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 168(10):1104–1110. doi: 10.1001/archinte.168.10.1104
  34. Lapane KL, Spooner JJ, Mucha L, Straus WL (2001) Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 49(5):577–584. doi: 10.1046/j.1532-5415.2001.49117.x
  35. Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D (2008) Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 103(4):872–882. doi: 10.1111/j.1572-0241.2008.01811.x